BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6530 related articles for article (PubMed ID: 3866512)

  • 1. [Experimental study of the antitumor anthracycline antibiotic aclarubicin (aclacinomycin A)].
    Egorov LV; Terent'eva TG; Rudneva NA; Egorenko GG; Ivanitskaia LP
    Antibiot Med Biotekhnol; 1985 Dec; 30(12):918-27. PubMed ID: 3866512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New anthracycline antibiotic aclacinomycin A: experimental studies and correlations with clinical trials.
    Oki T; Takeuchi T; Oka S; Umezawa H
    Recent Results Cancer Res; 1981; 76():21-40. PubMed ID: 6940212
    [No Abstract]   [Full Text] [Related]  

  • 3. [Aclacinomycin A: a new antitumor antibiotic].
    Egorov LV; Ivanitskaia LP; Navashin SM
    Antibiotiki; 1982; 27(7):540-55. PubMed ID: 6753735
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination chemotherapy with a new anthracycline glycoside, aclacinomycin-A, and active drugs for malignant lymphomas in P388 mouse leukemia system.
    Fujimoto S; Inagaki J; Horikoshi N; Ogawa M
    Gan; 1979 Aug; 70(4):411-20. PubMed ID: 92432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
    Fujimoto K; Oka T; Morimoto M
    Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study of new antineoplastic antibiotics based on newly discovered action mechanisms].
    Tanaka N
    Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1094-106. PubMed ID: 6191673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor efficacies of aclacinomycin A by oral administration.
    Tsukagoshi S; Tsuruo T; Yamori T; Iida H; Naganuma K; Sakurai Y
    J Pharmacobiodyn; 1980 Oct; 3(10):532-6. PubMed ID: 6937651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental and clinical studies on aclarubicin in the treatment of solid tumors.
    Kumai K; Kubota T; Ishibiki K; Abe O
    Biomed Pharmacother; 1984; 38(7):332-7. PubMed ID: 6596963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
    Wadler S; Fuks JZ; Wiernik PH
    J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
    Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
    Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines.
    Dong J; Naito M; Tatsuta T; Seimiya H; Johdo O; Tsuruo T
    Oncol Res; 1995; 7(5):245-52. PubMed ID: 8534930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.
    Goldin A; Venditti JM; Geran R
    Invest New Drugs; 1985; 3(1):3-21. PubMed ID: 3886588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experimental antimetastatic activity of aclarubicin].
    Viadro MM; Terent'eva TG
    Antibiot Khimioter; 1988 Nov; 33(11):845-8. PubMed ID: 3228327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aclarubicin inhibits etoposide induced apoptosis through inhibition of RNA synthesis in P388 murine leukemic cells.
    Nagata T; Higashigawa M; Shimono Y; Cao DC; Yan Mao X; M'soka T; Inamochi H; Hori H; Kawasaki H; Sakurai M
    J Exp Clin Cancer Res; 1998 Dec; 17(4):435-42. PubMed ID: 10089064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of mouse tumors with 7-con-O-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin.
    Neil GL; Kuentzel SL; McGovren JP
    Cancer Treat Rep; 1979; 63(11-12):1971-8. PubMed ID: 526931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of a new anthracycline antibiotic, aclacinomycin-A, in patients with advanced malignant lymphoma.
    Warrell RP; Kempin SJ
    Am J Clin Oncol; 1983 Feb; 6(1):81-4. PubMed ID: 6573124
    [No Abstract]   [Full Text] [Related]  

  • 17. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The antitumor activity of liposomal aclarubicin in vitro and in vivo].
    Viadro MM; Navashin SM
    Biull Eksp Biol Med; 1991 Nov; 112(11):523-5. PubMed ID: 1810495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
    Warrell RP; Arlin ZA; Kempin SJ; Young CW
    Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of Japanese studies with the new anthracycline antibiotic aclacinomycin A.
    Oki T; Takeuchi T; Oka S; Umezawa H
    Recent Results Cancer Res; 1980; 74():207-16. PubMed ID: 7003659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 327.